Tuesday, June 9, 2026
Running a day behind this week — we held the digest to capture the data coming out of the ADA Scientific Sessions in New Orleans, which ran through the weekend.
The week’s signal sits in two places. Diabetes tech dominated the news cycle out of ADA, with three of the major players posting pivotal data or label expansions and a notable tuck-in acquisition. Underneath that, a fresh wave of recalls and warning letters kept landing on quality systems and sterility — not core technology — a reminder that post-market exposure is where well-funded device makers are still getting caught. Capital kept moving regardless; M&A hasn’t cooled.
8 things to watch this week:
1. 🩸 Insulet posts pivotal Omnipod 6 and fully-closed-loop data at ADA
Insulet’s STRIVE pivotal trial showed improved glucose control with the next-gen Omnipod 6 versus Omnipod 5, while its EVOLUTION 3 study of a fully closed-loop system for type 2 diabetes lifted time-in-range to 64% and cut daily insulin from 86 to 58 units with no weight gain. A 2027 FDA filing and 2028 launch are the targets — the fully-closed-loop race is now the category’s real frontier. Drug Delivery Business + 2
Drug Delivery Business News
2. 🌐 Tandem wins expanded CE mark for type 2 and pregnancy use
Tandem’s t:slim X2 and Mobi pumps with Control-IQ+ are now CE-marked in Europe for adults with type 2 diabetes and for type 1 patients during pregnancy, backed by the 2IQP and CIRCUIT trials. Reimbursement and interoperability — not the algorithm — will decide who takes share as the closed-loop category matures. Medical Device Network
Medical Device Network
3. 🧭 Most medical device companies don’t fail on technology. They fail on sequencing.
The Commercial Launch & Impact Framework (CLIF) is a fast, external diagnostic that finds where your commercial story breaks — before a buyer or investor does. One week, an independent outside read, decision-grade clarity before you raise, launch, or scale.
Sponsored by RŌG Health
4. 🔬 Dexcom buys Nutrisense as level-A evidence backs CGM for type 2
At ADA, new data delivered the ADA’s highest (level A) evidence for continuous glucose monitors in type 2 non-insulin users, which Dexcom’s CEO expects to reshape the standard of care; the company also acquired metabolic-health firm Nutrisense. The CGM market is pushing decisively beyond insulin-dependent patients. MedTech Dive
MedTech Dive
5. ⚠️ BD recalls ChloraPrep and FREPP skin-prep lots over fungal contamination
BD is recalling lots of ChloraPrep Clear 1 mL and FREPP Clear 1.5 mL applicators over Aspergillus penicillioides contamination that the FDA warns can cause systemic infection, sepsis, and death if introduced during catheter placement. This is BD’s second ChloraPrep fungal recall in roughly a year — a sterility-control problem that isn’t going away. FDA
FDA
6. 🧪 Galmed pivots into GI medtech with $4.5M Colospan acquisition
Galmed signed a $4.5M definitive agreement to acquire Colospan, whose CG-100 intraluminal bypass device holds FDA Breakthrough Device status and a CE mark and is in a U.S. pivotal IDE trial; the device protects anastomotic connections after colorectal surgery and reduces the need for diverting stomas. A small deal, but a clean case study in how Breakthrough-designated devices are getting valued and acquired. Stock TitanMedical Buyer
Pharmaceutical Executive
7. 🏭 Boston Scientific to build $138M, 300-job distribution hub in Indiana
Boston Scientific will invest $138M in a 500,000-square-foot distribution and light-manufacturing facility in Plainfield, Indiana, expected to create up to 300 high-wage jobs, on top of recent investments in Ireland and Minnesota. Domestic logistics depth is becoming a competitive variable for the largest players. MassDevice
MassDevice
8. 🔧 Medline draws an FDA warning letter over cleanroom quality failures
The FDA cited 250 complaints on Medline’s angiographic syringes between June 2023 and February 2026, flagging particulate accumulation on manufacturing equipment and a last documented cleanroom-equipment cleaning dating to November 2023 — after which 114 foreign-matter complaints were logged. A textbook quality-system gap becoming a field problem. MedTech Dive
MedTech Dive
🔎 Bonus: worth a read
Founders face pressure from all sides as biotech crawls toward recovery
A dispatch from Salt Lake City’s Altitude Lab, where biotech founders — first-timers and 20-year veterans alike — talk candidly about raising capital in a risk-averse market that’s chasing AI hype over slow-moving science. A grounded look at the sequencing and storytelling challenges early-stage life science leaders are navigating right now.
BioSpace
Put your brand in front of 35,000+ medical device and med tech leaders each week. Contact us to learn more about sponsorship opportunities.
🧭 About The Pathway
The Pathway is a curated briefing for medical device leaders, focused on regulatory moves, product launches, partnerships, and market signals shaping the industry.
If this was useful, consider subscribing or sharing with a colleague who should be tracking these developments.
Some issues may include sponsored or partner content. Sponsorship does not influence editorial selection of third-party news items.